Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Evaxion
Historische aandelenkoersen
Huidige aandelenkoers	US$3.20
52 Week Hoogtepunt	US$12.15
52 Week Laag	US$2.26
Bèta	0.23
1 maand verandering	-20.00%
3 maanden verandering	-18.78%
1 Jaar Verandering	29.03%
3 jaar verandering	-95.08%
5 jaar verandering	-99.09%
Verandering sinds IPO	-99.35%

Recent nieuws en updates

Narratiefupdate • Jun 26

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Analysts have lowered their price target on Evaxion from $14.19 to $11.25, reflecting the application of a slightly higher discount rate and more moderate assumptions for revenue growth and profit margin, which in turn leads to a higher expected future P/E. What’s in the News for Evaxion Evaxion reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, with poster data set for presentation at the European Hematology Association 2026 Congress in Stockholm, Sweden.

Recent updates

Narratiefupdate • Jun 26

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Nieuw narratief • Mar 11

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?

Seeking Alpha • May 26

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Summary Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments). EVAX aims for at least 2 new deals in 2025 and is in the meantime further developing its AI platform to stay ahead of competition. Read the full article on Seeking Alpha

Seeking Alpha • Mar 31

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Summary Evaxion's sophisticated AI Immunology platform aims to outperform competitors in vaccine development, in both oncology and infectious diseases indications. The company has already established three collaborations, including a partnership with MSD, and has raised enough funding to last through 2024. Evaxion's AI models, including EDEN, RAVEN, PIONEER, ObsERV, and AI-DEEP, show promise in identifying protective antigens, designing effective and safe personalized cancer vaccines and predicting which patients will respond. Big pharma interest, pending catalysts in 2024, impressive proof-of-concept preclinical and clinical data are compelling enough for me for a small speculative position. However, the risk of considerably more dilutive funding as well as the very early stage of the pipeline make me give a "Hold" recommendation. Read the full article on Seeking Alpha

Seeking Alpha • Oct 05

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech (EVAX) said Wednesday Per Norlén joined the firm as CEO on Monday. Norlén is a physician and associate professor with over 20 years in the biotech sector, of which the last decade has been in executive leadership roles.

Seeking Alpha • Sep 21

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Evaxion Biotech (EVAX) said it enrolled its first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the the U.S., Europe, and Australia in collaboration with Merck (NYSE:MRK) which is supplying the trial with its blockbuster drug Keytruda, the Danish company said in a Sept. 21 press release. Patients will receive standard of care treatment along with Keytruda in combination with EVX-01. Evaxion added that it is responsible for conducting the trial. The company expects interim topline data in H2 2023. EVAX +11.27% to $2.27 premarket Sept. 21

Seeking Alpha • Aug 10

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Evaxion Biotech ADS press release (EVAX): Q2 GAAP EPS of -$0.20 beats by $0.10. As of June 30, 2022, cash and cash equivalents were $25.3M as compared to $32.2M as of December 31, 2021. We expect our existing cash and cash equivalents, including use of financing facilities, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.

Seeking Alpha • Aug 02

Evaxion Biotech announces new CEO as Lars Wegner resigns

Evaxion Biotech (EVAX) announced Tuesday the resignation of chief executive officer Lars Staal Wegner. The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in clinical pharmacology with over 20 years of working in clinical drug development. Most recently, Dr. Norlén was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB, Targinta is a wholly owned subsidiary of Xintela, a publicly listed company on the Nasdaq First North Growth Market Stockholm, Sweden. Earlier: Evaxion Biotech to advance DNA vaccine into non-small cell lung cancer indication

Rendement voor aandeelhouders

	EVAX	US Biotechs	US Markt
7D	-5.6%	6.1%	0.3%
1Y	29.0%	40.6%	19.9%

Rendement versus industrie: EVAX presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 40.6 % opleverde.

Rendement versus markt: EVAX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 19.9 %.

Prijsvolatiliteit

Is EVAX's price volatile compared to industry and market?
EVAX volatility
EVAX Average Weekly Movement	9.3%
Biotechs Industry Average Movement	10.5%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: EVAX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van EVAX is het afgelopen jaar gedaald van 16% naar 9%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	46	Helen Tayton-Martin	evaxion.ai

Evaxion A/S, een biotechbedrijf in een klinische fase, ontwikkelt immunologische vaccins op basis van kunstmatige intelligentie. Het bedrijf ontwikkelt EVX-01, dat zich in een wereldwijde multicenter klinische studie in fase 2 bevindt voor de behandeling van gevorderd melanoom; EVX-03, een op DNA gebaseerd kankervaccin voor de behandeling van vaste tumoren; en EVX-04, een therapeutisch kankervaccin dat zich in een fase 1 studie bevindt voor acute myeloïde leukemie. De programma's omvatten ook vaccins in pre-klinische fase, waaronder EVX-B1, een multi-component profylactisch vaccin tegen infecties van huid en weke delen met S. aureus bacteriën; EVX-B2 om een multi-component profylactisch vaccin tegen gonorroe bacteriën aan te pakken; EVX-B3 om bacteriële pathogenen aan te pakken die geassocieerd worden met herhaalde infecties; en EVX-V1, een multi-component profylactisch vaccin tegen cytomegalovirus.

Evaxion A/S Samenvatting

Hoe verhouden de winst en inkomsten van Evaxion zich tot de beurswaarde?
EVAX fundamentele statistieken
Marktkapitalisatie	US$27.36m
Inkomsten(TTM)	-US$9.76m
Inkomsten(TTM)	US$7.53m

3.5x

P/S-verhouding

-2.7x

Koers/Winstverhouding

Is EVAX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EVAX resultatenrekening (TTM)
Inkomsten	US$7.53m
Kosten van inkomsten	US$0
Brutowinst	US$7.53m
Overige uitgaven	US$17.28m
Inkomsten	-US$9.76m

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

Aug 20, 2026

Winst per aandeel (EPS)	-1.17
Brutomarge	100.00%
Nettowinstmarge	-129.60%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde EVAX op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/30 06:15
Aandelenkoers aan het einde van de dag	2026/06/29 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Evaxion A/S wordt gevolgd door 6 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Swayampakula Ramakanth	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Debanjana Chatterjee	JonesTrading Institutional Services, LLC

Evaxion (EVAX) Aandelenoverzicht

Beloningen

Risicoanalyse

Analyst Price Targets

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value

AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity

Top Community Narratives

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Top Community Narratives

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Top Analyst Narratives

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value

AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity

Evaxion A/S Concurrenten

Harvard Apparatus Regenerative Technology

Cyclerion Therapeutics

Apollomics

Pluri

Prijsgeschiedenis en prestaties

Recent nieuws en updates

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Evaxion A/S Presents New Preclinical Data For EVX-04, An Off-The-Shelf Therapeutic Vaccine For Acute Myeloid Leukemia

Evaxion A/S Promotes Birgitte Rønø as Chief Scientific and Chief Operating Officer

Evaxion A/S Demonstrates Scalability of Ai-Immunology Platform in Glioblastoma

Evaxion A/S Elects Jens Bitsch Nørhave to the Board of Directors

Evaxion A/S Announces Last Patient Visit in One-Year Extension of Phase 2 Trial with Personalized Cancer Vaccine Evx-01

Recent updates

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Evaxion A/S Presents New Preclinical Data For EVX-04, An Off-The-Shelf Therapeutic Vaccine For Acute Myeloid Leukemia

Evaxion A/S Promotes Birgitte Rønø as Chief Scientific and Chief Operating Officer

Evaxion A/S Demonstrates Scalability of Ai-Immunology Platform in Glioblastoma

Evaxion A/S Elects Jens Bitsch Nørhave to the Board of Directors

Evaxion A/S Announces Last Patient Visit in One-Year Extension of Phase 2 Trial with Personalized Cancer Vaccine Evx-01

Evaxion A S Presents Novel AI Based Polio Vaccine Design Concepts and Evx V1 Cmv Vaccine Program

Evaxion A/S, Annual General Meeting, Apr 16, 2026

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases

Evaxion A/S to Report Q3, 2026 Results on Nov 19, 2026

Evaxion A/S to Report Q3, 2025 Results on Nov 06, 2025

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces New Two-Year Unprecedented Clinical Efficacy Data of Its Personalized Cancer Vaccine EVX-01 in Patients with Advanced Melanoma

Evaxion A/S to Present New Biomarker Data for AI- Designed Personalized Cancer Vaccine EVX-01 At the SITC 2025 Annual Meeting

Evaxion A/S to Report Q2, 2025 Results on Aug 14, 2025

Evaxion A/S to Present Two-Year Clinical Efficacy Data from Phase 2 Trial with AI- Designed Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2025

Evaxion A/S Announces CEO Changes

Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion A/S to Report Q1, 2025 Results on May 27, 2025

Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of Ai- Designed Personalized Cancer Vaccine Evx-01

Evaxion Biotech A/S Presents striking EVX-01 Data at the AACR Annual Meeting

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $4.48 million.

Evaxion Biotech A/S Extends Phase 2 Trial with AI-Immunology™?

Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination

Evaxion Completes Dosing in Phase 2 Trial with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Establishes New AI-Derived Precision Cancer Vaccine Concept

Evaxion Biotech A/S has filed a Follow-on Equity Offering in the amount of $12.5 million.

Evaxion Announces Positive Preclinical Data for Cytomegalovirus (CMV) Vaccine Program EVX-V1

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.